|Shareholder/Beneficial Owner||Shares||% ISC|
|Lombard Odier Investment Managers||141,593,743||14.73|
|T Rowe Price Global Investments||93,927,465||9.77|
|Canaccord Genuity Wealth Management||85,007,125||8.84|
|Hargreaves Lansdown, stockbrokers||60,782,047||6.32|
|Dr Andrew Nelson*||46,266,881||4.81|
as at 30 June 2023
Quoted: AIM (London Stock Exchange)
Other Exchanges / Trading Platforms: The Company is not listed on any other exchanges or trading platforms.
Number of securities in issue: 961,386,955 Ordinary shares.
Shares not in public hands: Insofar as the Company is aware, the percentage of securities that is not in public hands is 36.3%, these being held by directors, their families and significant shareholders.
Own shares held in treasury: The Company holds 4,115 Ordinary Shares in treasury.
Details on any restrictions on the transfer of securities: There are no restrictions on the transfer of securities.
Applicable code(s): The Company is subject to the UK City Code on Takeovers and Mergers. The Code is administered by The Panel and Takeovers in Mergers.
* Per the Company’s RNS announcement of 11 May 2020, 12,121,711 Ordinary Shares of Dr Nelson’s total beneficial interest are subject to a Sale and Repurchase Agreement with Equities First Holdings.